Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.

PRP may increase hair density but doesn't improve quality of life in breast cancer survivors with hair loss.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.

The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

More research is needed to understand chemotherapy-induced hair loss and its phases.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

The patient showed tumor stability and improved health using a new Periwinkle preparation with chemotherapy.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.

Eyelash loss can temporarily occur from chemotherapy for retinoblastoma.

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

Tofacitinib might be used to treat hair loss.